Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Cipla
McKinsey
Citi
Merck
Moodys
QuintilesIMS
Covington
Daiichi Sankyo
Colorcon

Generated: January 16, 2018

DrugPatentWatch Database Preview

NORVIR Drug Profile

« Back to Dashboard

When do Norvir patents expire, and what generic alternatives are available?

Norvir is a drug marketed by Abbott, Abbvie, and Abbvie Inc. and is included in five NDAs. There are eleven patents protecting this drug and two Paragraph IV challenges.

This drug has seventy-eight patent family members in thirty-one countries and three supplementary protection certificates in three countries.

The generic ingredient in NORVIR is ritonavir. There are twenty-one drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ritonavir profile page.

US Patents and Regulatory Information for NORVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott NORVIR ritonavir CAPSULE;ORAL 020680-001 Mar 1, 1996 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc NORVIR ritonavir POWDER;ORAL 209512-001 Jun 7, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie NORVIR ritonavir SOLUTION;ORAL 020659-001 Mar 1, 1996 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for NORVIR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 ➤ Subscribe ➤ Subscribe
Abbott NORVIR ritonavir CAPSULE;ORAL 020680-001 Mar 1, 1996 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 ➤ Subscribe ➤ Subscribe
Abbott NORVIR ritonavir CAPSULE;ORAL 020680-001 Mar 1, 1996 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir SOLUTION;ORAL 020659-001 Mar 1, 1996 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir SOLUTION;ORAL 020659-001 Mar 1, 1996 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir SOLUTION;ORAL 020659-001 Mar 1, 1996 ➤ Subscribe ➤ Subscribe
Abbvie NORVIR ritonavir CAPSULE;ORAL 020945-001 Jun 29, 1999 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for NORVIR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules 100 mg ➤ Subscribe 10/31/2012
➤ Subscribe Tablets 100 mg ➤ Subscribe 12/21/2010

Non-Orange Book US Patents for NORVIR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,659,405 Polymorph of a pharmaceutical ➤ Subscribe
8,333,990 Solid pharmaceutical dosage form ➤ Subscribe
6,458,818 Pharmaceutical composition ➤ Subscribe
9,255,092 Polymorph of a pharmaceutical ➤ Subscribe
8,377,952 Solid pharmaceutical dosage formulation ➤ Subscribe
6,521,651 Pharmaceutical composition ➤ Subscribe
8,193,367 Polymorph of a pharmaceutical ➤ Subscribe
7,183,416 Polymorph of a pharmaceutical ➤ Subscribe
6,894,171 Polymorph of a pharmaceutical ➤ Subscribe
8,309,613 Solid pharmaceutical dosage form ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for NORVIR

Supplementary Protection Certificates for NORVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00060 Netherlands ➤ Subscribe PRODUCT NAME: RITONAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN FARMACEUTISCH AANVAARDBARE ESTER, EN LOPINAVIR; REGISTRATION NO/DATE: EU/1/01/172/001 - EU/1/01/172/003 20010320
C/GB01/044 United Kingdom ➤ Subscribe PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320
0674513 Switzerland ➤ Subscribe PRODUCT NAME: LOPINAVIR UND RITONAVIR; REGISTRATION NO/DATE: IKS 55648 20001213
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Healthtrust
Accenture
Federal Trade Commission
Johnson and Johnson
US Army
Farmers Insurance
QuintilesIMS
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot